Complicated Intra-Abdominal Infection Clinical Trial
Official title:
A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults
The purpose of this study is to evaluate the effects of Ceftazidime Avibactam plus Metronidazole compared to Meropenem for treating hospitalized patients with complicated intra-abdominal infections.
A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05905055 -
P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales
|
Phase 3 | |
| Completed |
NCT03293485 -
Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)
|
Phase 3 | |
| Completed |
NCT04927312 -
Study to Assess Efficacy and Safety of PF-06947386 in Japanese Adult Patients With Complicated Intra-abdominal Infection
|
Phase 3 | |
| Completed |
NCT00929643 -
Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections
|
N/A | |
| Completed |
NCT01147640 -
Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections
|
Phase 2 | |
| Not yet recruiting |
NCT05148702 -
EXTENDed Antibiotic Durations Compared to Standard Durations for Patients With Complicated Intra-abdominal Infection.
|
Phase 3 | |
| Completed |
NCT01644643 -
Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens
|
Phase 3 | |
| Completed |
NCT01726023 -
Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections
|
Phase 3 | |
| Withdrawn |
NCT00914888 -
Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia
|
Phase 3 | |
| Completed |
NCT01265784 -
Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections
|
Phase 2 | |
| Withdrawn |
NCT01602874 -
Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia
|
Phase 3 | |
| Completed |
NCT00157898 -
A Study to Evaluate Ertapenem Versus It's Comparator in the Treatment of Complicated Intra-abdominal Infections in Adults (0826-050)(COMPLETED)
|
Phase 4 | |
| Recruiting |
NCT05733104 -
A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea
|
||
| Completed |
NCT01445678 -
Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections
|
Phase 3 | |
| Completed |
NCT02739997 -
Study of Ceftolozane/Tazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013)
|
Phase 3 | |
| Completed |
NCT03329092 -
A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.
|
Phase 3 | |
| Completed |
NCT03217136 -
MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)
|
Phase 2 | |
| Completed |
NCT01500239 -
A Study Comparing Ceftazidime-Avibactam+Metronidazole Versus Meropenem in Adults With Complicated Intra-abdominal Infections
|
Phase 3 |